China National Pharmaceutical Group: Achieve revenue of 31.83 billion yuan by 2025, with AI technology deeply empowering the company's entire industry chain

Ask AI · How can AI technology help China Biopharmaceutical R&D efficiency improve by 50%?

On March 26, China Biopharmaceutical released its 2025 full-year performance report. For the full year, the company achieved revenue of RMB 31.83 billion, up 10.3% year over year. Adjusted Non-HKFRS attributable net profit was RMB 4.54 billion, up 31.4% year over year. Both revenue and net profit hit record highs.

As a benchmark domestic pharmaceutical company in its innovation-driven transformation, China Biopharmaceutical’s growth has long shed reliance on a single product and formed a growth pattern driven by innovative products with coordinated efforts across multiple areas, achieving steady growth that has sustained through industry cycles. From 2023 to 2025, the company’s revenue from innovative products increased from RMB 9.89 billion to RMB 15.22 billion, with a compound annual growth rate of over 24%. In 2025, the year-over-year growth rate reached 26.2% as well.

At the same time, the company’s profitability has continued to improve steadily. In 2025, its overall gross margin reached 82.1%, up another 0.6 percentage points from the previous year. For three consecutive years, it has remained on an upward trend, firmly maintaining its position in the top tier of the industry. The continued rise in gross margin benefits not only from the growing share of revenue from high-gross-margin innovative products, but also from efficiency upgrades on the company’s production side—driven by the substantial capacity increase enabled by the 10000L biologics production line, as well as the combination of full-dosage-form production capability with end-to-end intelligent management. By doing so, the company has achieved triple leadership in production cost, production efficiency, and product quality, laying a solid foundation for the continued improvement in profitability.

The announcement notes that, currently, AI technology has already expanded from R&D, production, and sales to functional management, achieving full-chain coverage of the company’s operations. For example, on the R&D side, an AI-enabled platform has improved PCC discovery time by more than 50%, shortened the clinical screening cycle by about 30%, and delivered a dual improvement in R&D efficiency and the input-output ratio. On the marketing side, relying on a precise marketing system built with an “AI marketing brain,” it drives the continued acceleration of average output per marketing employee and continuously optimizes operating efficiency. While the company’s scale keeps expanding, it also achieves a synchronized improvement in operational efficiency—this is the core reflection of a leading enterprise’s capabilities in refined management.

At the company’s earnings call, it said that over the past three years, the group has cumulatively obtained approvals for 16 innovative products, including 7 Category 1 innovative drugs in China, with innovation成果转化 efficiency leading the industry. Over the next three years, the company’s innovative pipeline is expected to enter a new round of explosive growth. About 20 innovative drugs or new indications are expected to be approved for上市. It is expected that by the end of 2028, the company’s total number of innovative products will exceed 40.

(China Biopharmaceutical)